Nicholas Botwood Bought 50% More Shares In Syndax Pharmaceuticals

Investors who take an interest in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) should definitely note that insider Nicholas Botwood recently paid US$9.00 per share to buy US$106k worth of the stock. We reckon that's a good sign, especially since the purchase boosted their holding by 50%.

We've discovered 2 warning signs about Syndax Pharmaceuticals. View them for free.

The Last 12 Months Of Insider Transactions At Syndax Pharmaceuticals

The CEO & Director, Michael Metzger, made the biggest insider sale in the last 12 months. That single transaction was for US$206k worth of shares at a price of US$15.50 each. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (US$10.57). So it may not tell us anything about how insiders feel about the current share price.

In the last twelve months insiders purchased 28.02k shares for US$267k. But they sold 21.68k shares for US$336k. All up, insiders sold more shares in Syndax Pharmaceuticals than they bought, over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

See our latest analysis for Syndax Pharmaceuticals

I will like Syndax Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

Does Syndax Pharmaceuticals Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 0.7% of Syndax Pharmaceuticals shares, worth about US$5.5m, according to our data. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

So What Does This Data Suggest About Syndax Pharmaceuticals Insiders?

It's certainly positive to see the recent insider purchases. But we can't say the same for the transactions over the last 12 months. Neither the level of insider ownership, nor the transactions over the last twelve months inspire us, but we think the recent buying is positive. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Syndax Pharmaceuticals. In terms of investment risks, we've identified 2 warning signs with Syndax Pharmaceuticals and understanding these should be part of your investment process.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.